Literature DB >> 1100518

Endocytosis of chlorambucil-bound anti-tumor globulin following "capping" in EL4 lymphoma cells.

A Guclu, J Tai, T Ghose.   

Abstract

A rabbit 7 S antibody reacting specifically with a tumor assoicated antigen on the surface of mouse EL4 lymphoma cells could form "caps" and subsequently undergo endocytosis even when the antibody was non-covalently bound to chlorambucil. As the alkylation of nuclear DNA appears to be the basis of tumor inhibition by alkylating agents like chlorambucil, facilitation of the transport of chlorambucil across cell membrane by anti-tumor antibodies might explain, at least in part, the increased tumor inhibition by cholorambucil bound anti-tumor antibodies compared to tumor inhibition by equivalent amounts of tumor antibodies or chlorambucil alone.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1100518     DOI: 10.3109/08820137409055776

Source DB:  PubMed          Journal:  Immunol Commun        ISSN: 0090-0877


  5 in total

1.  Electron microscopic and radioisotopic studies on cap formation in Toxoplasma gondii.

Authors:  T H Dzbenski; T Michalak; W S Plonka
Journal:  Infect Immun       Date:  1976-11       Impact factor: 3.441

2.  Uptake of methotrexate linked to an anti-EL4-lymphoma antibody by EL4 cells.

Authors:  P Uadia; A H Blair; T Ghose
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

Review 3.  Oncostatic-antibody complexes in chemotherapy.

Authors:  H F Dullens; R A De Weger
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

4.  Inhibition of a mouse hepatoma by the alkylating agent Trenimon linked to immunoglobulins.

Authors:  T Ghose; A Guclu; R R Raman; A H Blair
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

5.  Antibody directed targeting of methotrexate-containing small unilamellar vesicles.

Authors:  M Singh; G Faulkner; T I Ghose; M Mezei
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.